Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062755) Bispecific antibodies against EGFR and PD-1
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062755 International Application No.: PCT/CN2018/107582
Publication Date: 04.04.2019 International Filing Date: 26.09.2018
IPC:
C07K 16/28 (2006.01) ,C07K 16/46 (2006.01) ,A61K 39/395 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
WUXI BIOLOGICS (SHANGHAI) CO., LTD. [CN/CN]; 299 Fute Zhong Road, Pudong Shanghai 200131, CN
WUXI BIOLOGICS (CAYMAN) INC.; P.O. Box 309 Ugland House Grand Cayman KYl-1104, KY
Inventors:
WANG, Zhuozhi; CN
LI, Jing; US
Agent:
ANJIE LAW FIRM; 19/F, Tower D1 Liangmaqiao Diplomatic Office Building No. 19 Dongfangdonglu, Chaoyang District Beijing 100600, CN
Priority Data:
PCT/CN2017/10458429.09.2017CN
Title (EN) Bispecific antibodies against EGFR and PD-1
(FR) ANTICORPS BISPÉCIFIQUES DIRIGÉS CONTRE EGFR ET PD-1
Abstract:
(EN) Bispecific antibodies comprise first binding domain which binds to EGFR and a second binding domain which binds to PD-1, wherein the antibody or the antigen binding-fragment is in a format selected from the group consisting of single chain Fv (scFv), diabodies, and oligomers of the foregoing formats. Amino acid sequences of the antibodies, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies are provided. Therapeutic compositions comprising the antibodies and methods for treating cancers and other diseases with the bispecific antibodies are also provided.
(FR) La présente invention concerne des anticorps bispécifiques comprenant un premier domaine de liaison qui se lie à EGFR et un second domaine de liaison qui se lie à PD-1, l'anticorps ou le fragment de liaison à l'antigène étant dans un format choisi dans le groupe constitué par un Fv à chaîne unique (scFv), des dianticorps et des oligomères de formats précédents. L'invention concerne également des séquences d'acides aminés des anticorps, des vecteurs de clonage ou d'expression, des cellules hôtes et des procédés d'expression ou d'isolement d'anticorps. L'invention concerne en outre des compositions thérapeutiques comprenant les anticorps et des méthodes de traitement de cancers et d'autres maladies avec les anticorps bispécifiques.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)